Key result
The combination of AN-7 and doxorubicin significantly reduced mean tumor weight to 0.71 g compared to 2.05 g with vehicle, while simultaneously protecting against doxorubicin-induced cardiotoxicity.
Why the study?
Does the combination of AN-7 and doxorubicin improve anticancer efficacy and prevent doxorubicin-induced cardiotoxicity in mice bearing mammary tumors?
Population
Eight- to ten-week old female BALB/c mice implanted subcutaneously with 4T1 mammary carcinoma cells (n=56).
Comparison
Combination of AN-7 and doxorubicin. vs Vehicle control, doxorubicin alone, or AN-7 alone.
Design
Preclinical, Mice were randomly divided into 4 equal groups., Metastatic…
Follow-up
25 days
Authors
Loading...
May support dual benefit in murine models; hypothesis-generating for clinical translation in cardio-oncology.
Does the combination of AN-7 and doxorubicin improve anticancer efficacy and prevent doxorubicin-induced cardiotoxicity in mice bearing mammary tumors?
Absolute Event Rate: 0.71% vs 2.05%
p-value: p=<0.05
The combination of the histone deacetylase inhibitor AN-7 and doxorubicin synergistically improves anticancer efficacy while protecting against doxorubicin-induced cardiotoxicity in a murine breast cancer model.
Tarasenko et al. (2012) studied Mammary tumor (n=56). AN-7 and Doxorubicin vs. Vehicle (saline) was evaluated on Tumor weight at day 25 (p=<0.05). The combination of AN-7 and doxorubicin significantly reduced mean tumor weight to 0.71 g compared to 2.05 g with vehicle, while simultaneously protecting against doxorubicin-induced cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: